High-throughput screening for daunorubicin-mediated drug resistance identifies mometasone furoate as a novel ABCB1-reversal agent

Journal of Biomolecular Screening

Volumn 13, Issue 3, 2008, Pages 185-193

  Winter, Stuart S ^a,b   Lovato, Debbie M ^a   Khawaja, Hadya M ^a   Edwards, Bruce S ^a   Steele, Irena D ^a   Young, Susan M ^a   Oprea, Tudor I ^a   Sklar, Larry A ^a   Larson, Richard S ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

ABCB1; High throughput screening; Prestwick Chemical Library; T ALL; Transporter related multidrug resistance

Indexed keywords

ASPARAGINASE; BEPRIDIL; BREAST CANCER RESISTANCE PROTEIN; CYCLOSPORIN A; DAUNORUBICIN; FLUORESCENT DYE; GLYCOPROTEIN P; KETOCONAZOLE; MOMETASONE FUROATE; MULTIDRUG RESISTANCE PROTEIN 1; NICARDIPINE; PREDNISOLONE; PROPAFENONE; RESCINNAMINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

BIOLOGICAL ASSAY; CARBOCYANINES; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; JURKAT CELLS; P-GLYCOPROTEIN; PREGNADIENEDIOLS; UP-REGULATION;

EID: 40049099575     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057108314610     Document Type: Article

References (27)

1. Leonard GD, Fojo T., Bates SE: The role of ABC transporters in clinical practice. Oncologist 2003 ; 8: 411-424.
2. Altenberg GA: Structure of multidrug-resistance proteins of the ATPbinding cassette (ABC) superfamily. Curr Med Chem Anti-Cancer Agents 2004 ; 4: 53-62.
3. Wada M.: Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response. Cancer Lett 2006 ; 234: 40-50.
4. Styczynski J., Koltan A., Haus O., Wysocki M.: Differential chemosensitivity in a child with congenital relapsing acute lymphoblastic leukemia. Pediatr Hematol Oncol 2002 ; 19: 355-360.
5. Kanerva J., Tiirikainen M., Makipernaa A., Riikonen P., Mottonen M., Salmi TT,, et al. Multiple drug resistance mediated by P-glycoprotein is not a major factor in a slow response to therapy in childhood ALL. Pediatr Hematol Oncol 1998 ; 15: 11-21.
6. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J.,, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994 ; 12: 835-842.
7. Young SM, Bologa C., Prossnitz ER, Oprea TI, Sklar LA, Edwards BS: High-throughput screening with HyperCyt flow cytometry to detect small molecule formylpeptide receptor ligands. J Biomol Screen 2005 ; 10: 374-382.
8. Legrand O., Perrot JY, Simonin G., Baudard M., Marie JP: JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. Blood 2001 ; 97: 502-508.
9. Kuhnel JM, Perrot JY, Faussat AM, Marie JP, Schwaller MA: Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia 1997 ; 11: 1147-1155.
10. Estes DA, Lovato DM, Khawaja HM, Winter SS, Larson RS: Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples. Br J Haematol 2007 ; 139: 20-30.
11. Winter SS, Jiang Z., Khawaja HM, Griffin T., Devidas M., Asselin BL,, et al. Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2007 ; 110: 1429-1438.
12. Edwards BS, Bologa C., Young SM, Balakin KV, Prossnitz ER, Savchuck NP,, et al. Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Mol Pharmacol 2005 ; 68: 1301-1310.
13. Winter SS, Holdsworth MT, Devidas M., Raisch DW, Chauvenet A., Ravindranath Y.,, et al. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296. Pediatr Blood Cancer 2006 ; 46: 179-186.
14. Jamroziak K., Robak T.: Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology 2004 ; 9: 91-105.
15. Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E., Crabtree GR: Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 1989 ; 246: 1617-1620.
16. Vreugdenhil G., Raemaekers JM, van Dijke BJ, de Pauw BE: Itraconazole and multidrug resistance: possible effects on remission rate and disease-free survival in acute leukemia. Ann Hematol 1993 ; 67: 107-109.
17. Linn SC, van Kalken CK, van Tellingen O., van der Valk P., van Groeningen CJ, Kuiper CM,, et al. Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil. J Clin Oncol 1994 ; 12: 812-819.
18. Petrini M., Caracciolo F., Carulli G., Conte A., Sabbatini A., Mattii L.,, et al. Vitamin D3 administration and multidrug resistance in acute nonlymphoblastic leukemia. Acta Haematol 1993 ; 89: 184-188.
19. Lacayo NJ, Lum BL, Becton DL, Weinstein H., Ravindranath Y., Chang MN,, et al. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia 2002 ; 16: 920-927.
20. Poroikov VV, Filimonov DA: How to acquire new biological activities in old compounds by computer prediction. J Comput Aided Mol Des 2002 ; 16: 819-824.
21. Takagi T., Ramachandran C., Bermejo M., Yamashita S., Yu LX, Amidon GL: A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm 2006 ; 3: 631-643.
22. Wu CY, Benet LZ: Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005 ; 22: 11-23.
23. Nobili S., Landini I., Giglioni B., Mini E.: Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006 ; 7: 861-879.
24. Hegewisch-Becker S.: MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Leukemia 1996 ; 10 (suppl 3). S32 - S38.
25. Gottesman MM, Fojo T., Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002 ; 2: 48-58.
26. Robert J., Jarry C.: Multidrug resistance reversal agents. J Med Chem 2003 ; 46: 4805-4817.
27. Bates SF, Chen C., Robey R., Kang M., Figg WD, Fojo T.: Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found Symp 2002 ; 243: 83-96 ; discussion 96-102, 180-105.